1. Home
  2. IDN vs IMUX Comparison

IDN vs IMUX Comparison

Compare IDN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

HOLD

Current Price

$4.33

Market Cap

163.7M

Sector

Technology

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$11.55

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDN
IMUX
Founded
1994
2016
Country
United States
United States
Employees
N/A
66
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.7M
152.6M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
IDN
IMUX
Price
$4.33
$11.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$7.33
$36.00
AVG Volume (30 Days)
621.4K
845.2K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
220.00
38.00
EPS
0.03
N/A
Revenue
$4,433,454.00
N/A
Revenue This Year
$12.54
N/A
Revenue Next Year
$15.32
N/A
P/E Ratio
$140.00
N/A
Revenue Growth
23.21
N/A
52 Week Low
$3.67
$0.51
52 Week High
$9.08
$13.30

Technical Indicators

Market Signals
Indicator
IDN
IMUX
Relative Strength Index (RSI) 24.47 72.08
Support Level N/A $0.75
Resistance Level $5.34 $13.30
Average True Range (ATR) 0.47 0.95
MACD -0.44 -0.21
Stochastic Oscillator 7.22 56.74

Price Performance

Historical Comparison
IDN
IMUX

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: